King's College London

Research portal

Cell therapy in organ transplantation: Our experience on the clinical translation of regulatory T cells

Research output: Contribution to journalReview article

Standard

Cell therapy in organ transplantation : Our experience on the clinical translation of regulatory T cells. / Safinia, Niloufar; Grageda, Nathali; Scottà, Cristiano; Thirkell, Sarah; Fry, Laura J.; Vaikunthanathan, Trishan; Lechler, Robert I.; Lombardi, Giovanna.

In: Frontiers in Immunology, Vol. 9, No. FEB, 354, 02.2018.

Research output: Contribution to journalReview article

Harvard

Safinia, N, Grageda, N, Scottà, C, Thirkell, S, Fry, LJ, Vaikunthanathan, T, Lechler, RI & Lombardi, G 2018, 'Cell therapy in organ transplantation: Our experience on the clinical translation of regulatory T cells', Frontiers in Immunology, vol. 9, no. FEB, 354. https://doi.org/10.3389/fimmu.2018.00354

APA

Safinia, N., Grageda, N., Scottà, C., Thirkell, S., Fry, L. J., Vaikunthanathan, T., Lechler, R. I., & Lombardi, G. (2018). Cell therapy in organ transplantation: Our experience on the clinical translation of regulatory T cells. Frontiers in Immunology, 9(FEB), [354]. https://doi.org/10.3389/fimmu.2018.00354

Vancouver

Safinia N, Grageda N, Scottà C, Thirkell S, Fry LJ, Vaikunthanathan T et al. Cell therapy in organ transplantation: Our experience on the clinical translation of regulatory T cells. Frontiers in Immunology. 2018 Feb;9(FEB). 354. https://doi.org/10.3389/fimmu.2018.00354

Author

Safinia, Niloufar ; Grageda, Nathali ; Scottà, Cristiano ; Thirkell, Sarah ; Fry, Laura J. ; Vaikunthanathan, Trishan ; Lechler, Robert I. ; Lombardi, Giovanna. / Cell therapy in organ transplantation : Our experience on the clinical translation of regulatory T cells. In: Frontiers in Immunology. 2018 ; Vol. 9, No. FEB.

Bibtex Download

@article{c3be39d3e19b4c928e0446dd3c7aa81f,
title = "Cell therapy in organ transplantation: Our experience on the clinical translation of regulatory T cells",
abstract = "Solid organ transplantation is the treatment of choice for patients with end-stage organ dysfunction. Despite improvements in short-term outcome, long-term outcome is suboptimal due to the increased morbidity and mortality associated with the toxicity of immunosuppressive regimens and chronic rejection (1-5). As such, the attention of the transplant community has focused on the development of novel therapeutic strategies to achieve allograft tolerance, a state whereby the immune system of the recipient can be re-educated to accept the allograft, averting the need for long-term immunosuppression. Indeed, reports of {"}operational{"} tolerance, whereby the recipient is offall immunosuppressive drugs and maintaining good graft function, is well documented in the literature for both liver and kidney transplantations (6-8). However, this phenomenon is rare and in the setting of liver transplantation has been shown to occur late after transplantation, with the majority of patients maintained on life-long immunosupression to prevent allograft rejection (9). As such, significant research has focused on immune regulation in the context of organ transplantation with regulatory T cells (Tregs) identified as cells holding considerable promise in this endeavor. This review will provide a brief introduction to human Tregs, their phenotypic and functional characterization and focuses on our experience to date at the clinical translation of Treg immunotherapy in the setting of solid organ transplantation.",
keywords = "Cell therapy, Clinical trials, Good manufacturing practice, Regulatory T cells, Technical transfer, Transplantation",
author = "Niloufar Safinia and Nathali Grageda and Cristiano Scott{\`a} and Sarah Thirkell and Fry, {Laura J.} and Trishan Vaikunthanathan and Lechler, {Robert I.} and Giovanna Lombardi",
year = "2018",
month = feb,
doi = "10.3389/fimmu.2018.00354",
language = "English",
volume = "9",
journal = "Frontiers in Immunology",
issn = "1664-3224",
number = "FEB",

}

RIS (suitable for import to EndNote) Download

TY - JOUR

T1 - Cell therapy in organ transplantation

T2 - Our experience on the clinical translation of regulatory T cells

AU - Safinia, Niloufar

AU - Grageda, Nathali

AU - Scottà, Cristiano

AU - Thirkell, Sarah

AU - Fry, Laura J.

AU - Vaikunthanathan, Trishan

AU - Lechler, Robert I.

AU - Lombardi, Giovanna

PY - 2018/2

Y1 - 2018/2

N2 - Solid organ transplantation is the treatment of choice for patients with end-stage organ dysfunction. Despite improvements in short-term outcome, long-term outcome is suboptimal due to the increased morbidity and mortality associated with the toxicity of immunosuppressive regimens and chronic rejection (1-5). As such, the attention of the transplant community has focused on the development of novel therapeutic strategies to achieve allograft tolerance, a state whereby the immune system of the recipient can be re-educated to accept the allograft, averting the need for long-term immunosuppression. Indeed, reports of "operational" tolerance, whereby the recipient is offall immunosuppressive drugs and maintaining good graft function, is well documented in the literature for both liver and kidney transplantations (6-8). However, this phenomenon is rare and in the setting of liver transplantation has been shown to occur late after transplantation, with the majority of patients maintained on life-long immunosupression to prevent allograft rejection (9). As such, significant research has focused on immune regulation in the context of organ transplantation with regulatory T cells (Tregs) identified as cells holding considerable promise in this endeavor. This review will provide a brief introduction to human Tregs, their phenotypic and functional characterization and focuses on our experience to date at the clinical translation of Treg immunotherapy in the setting of solid organ transplantation.

AB - Solid organ transplantation is the treatment of choice for patients with end-stage organ dysfunction. Despite improvements in short-term outcome, long-term outcome is suboptimal due to the increased morbidity and mortality associated with the toxicity of immunosuppressive regimens and chronic rejection (1-5). As such, the attention of the transplant community has focused on the development of novel therapeutic strategies to achieve allograft tolerance, a state whereby the immune system of the recipient can be re-educated to accept the allograft, averting the need for long-term immunosuppression. Indeed, reports of "operational" tolerance, whereby the recipient is offall immunosuppressive drugs and maintaining good graft function, is well documented in the literature for both liver and kidney transplantations (6-8). However, this phenomenon is rare and in the setting of liver transplantation has been shown to occur late after transplantation, with the majority of patients maintained on life-long immunosupression to prevent allograft rejection (9). As such, significant research has focused on immune regulation in the context of organ transplantation with regulatory T cells (Tregs) identified as cells holding considerable promise in this endeavor. This review will provide a brief introduction to human Tregs, their phenotypic and functional characterization and focuses on our experience to date at the clinical translation of Treg immunotherapy in the setting of solid organ transplantation.

KW - Cell therapy

KW - Clinical trials

KW - Good manufacturing practice

KW - Regulatory T cells

KW - Technical transfer

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=85042566421&partnerID=8YFLogxK

U2 - 10.3389/fimmu.2018.00354

DO - 10.3389/fimmu.2018.00354

M3 - Review article

AN - SCOPUS:85042566421

VL - 9

JO - Frontiers in Immunology

JF - Frontiers in Immunology

SN - 1664-3224

IS - FEB

M1 - 354

ER -

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454